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Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia TO 
THE EDITOR
Acute promyelocytic leukemia (APL) accounts for 5-10% of all acute myelogeneous leukemias (AML). APL is characterized by a maturation arrest of the leukemic cells at the promyelocytic stage, occurrence of coagulopathy, and the presence of a specific cytogenetic abnormality t(15;17) with the molecular rearrangement PML/RAR␣. Prognosis of APL has improved impressively due to the introduction of the differentiating agent all-trans retinoic acid (ATRA). With the combination of ATRA and chemotherapy, an improvement of complete remission (CR) rate and overall survival, and a reduction of early mortality and relapse rates have been observed in patients presenting either APL de novo, [1] [2] [3] resistant disease 4 or relapse. 5 We read with interest the article by Estey et al 6 concerning the association between increased body mass index (BMI) and APL in patients with AML. The authors' present data, obtained from 1245 patients with newly diagnosed AML of whom 120 had APL, showed an association between APL and obesity. 6 Although realized on a smaller series, a similar study carried out on our recent patients tends to confirm these results. The BMI, calculated as weight in kg/(height in meters) 2 and used as the measure of obesity, showed a mean value of 27.4 with a standard deviation of 4.3 (median value 26.1) in the last 27 APL patients (median age 43 years) seen in our institution, while BMI was 24.8 ± 3.7 (median value 24.6) in a cohort of 73 successive adult non-APL patients with AML (median age 66 years) corresponding to our patients included in the EORTC AML-10 and AML-13 protocols, and 23.1 ± 3.8 (median value 22.6) in a cohort of 45 successive adult patients with acute lymphoblastic leukemia (median age 42 years) corresponding to our patients included in the LALA-94 protocols for young and elderly adults. The higher mean value of BMI in APL patients comparatively to non-APL patients was confirmed when considering patients according to age ( Figure 1 ) and sex ( Figure 2 Drug doses used in the treatment of leukemia are usually calculated according to body-surface area and do not take into account the fat mass. Avoidance of drug toxicity is highly dependent on the schedule of drug administration and requires a choice in the duration of administration, frequency of repetition of the dose, and the sequencing of multiple drugs. Among the most widely used antineoplastic agents, the anthracycline antibiotics can cause a cardiac toxic reaction of great concern. Since the landmark paper of Bernard et al, 7 all main studies have incorporated anthracyclines as part of therapy in APL. With a standard schedule, cardiac toxicity develops as a result of cumulative injury to the myocardium, producing initial progressive disappearance of myofibrils from the cells to the late development of diffuse myocardial fibrosis. For daunorubicin, the most commonly used total dose limit is 900-1000 mg/m 2 . However, fatal congestive cardiomyopathies have been observed after a single dose, and congestive heart failure may occur many months after the discontinuation of anthracyclines.
Therefore, because of a risk of overdose chemotherapy, the wide use of cardiotoxic agents and the method of determining
Figure 1
Body mass index: comparison between leukemias according to age.
Figure 2
Body mass index: comparison between leukemias according to sex. drug doses may be questionable in obese leukemic patients (defined by BMI Ͼ27). Because of their tendency to have an increased BMI and long survival, this causes particular concern in APL patients. In order to illustrate this, we report two overweight APL patients who after treatment developed severe cardiac toxicity requiring cardiac transplantation.
Case 1, a 25-year-old woman, was first admitted to hospital complaining of bleeding gums, spontaneous bruising and headache in February 1990. Her height was 1.6 meter and her weight was 86 kg (BMI 33.6). Peripheral blood showed pancytopenia. The bone marrow was markedly hypercellular and had typical findings of APL with hypergranular blasts, many with multiple Auer rods. Cytogenetic She was re-treated according to the schedule of APL-91 protocol 9 and received oral ATRA (45 mg/m 2 /day) from day 1 to CR achievement. CR was achieved by day 51. Then the patient received chemotherapy including daunorubicin 60 mg/m 2 /day for 3 days, and cytarabine 200 mg/m 2 /day for 7 days. First consolidation was similar to re-induction chemotherapy. Second consolidation included daunorubicin 45/mg/m 2 /day for 3 days, and cytarabine 1 g × 2/m 2 /day for 4 days. Overall, the patient received during treatment 1779 mg of daunorubicin, while she would only have received 1449 mg if she had presented with 'ideal' weight as defined by standard height-weight tables. 10 The patient, presenting with dyspnea, orthopnea and paroxysmal nocturnal dyspnea was re-hospitalized by October 1992. The echocardiogram showed a cardiac left-sided failure with a mural thrombi lodged in the left ventricle and symptomatic medical treatment was instituted. The insidious onset of cardiac failure with fatigue, weakness, anorexia and decreased tissue mass (weight 49 kg) progressively occurred. A cardiac transplantation was finally realized in February 1994 producing recovery to a normal quality of life. The patient is currently alive more than 5. year after her second CR. She is still in cytological CR and has no detectable PML/RAR␣ rearrangement by RT-PCR determinations.
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Case 2, a 34-year-old women, was first admitted to the hospital with asthenia, hemorrhages and coagulopathy in March 1988. Peripheral blood showed anemia, thrombocytopenia and white blood cell count of 3.8 × 10 9 /l (62% blasts with abundance of Auer bodies). Her height was 1.6 meter and her weight was 67 kg (BMI 26.1). Bone marrow aspirates showed an infiltration by 90% of leukemic cells with t(15;17) confirming the diagnosis of typical promyelocytic leukemia. Treatment was started according to LYLAM85 protocol 8 with daunorubicin, 6-MP and cytarabine. By day 31, bone marrow aspirate still showed 70% of blast cells and the patient received salvage therapy including high-dose cytarabine for 4 days and amsacrine for 3 days. CR was finally achieved by day 27 of combined therapy after a period of pancytopenia without major complication. A consolidation course was started in July 1988 including daunorubicin 45 mg/m 2 /day from day 1 to day 3, and cytarabine 500 mg/m 2 /day from day 1 to day 3 and from day 8 to day 10, according to the protocol schedule. Relapsed occurred in June 1990, revealed by pancytopenia and coagulopathy. Her weight was then 75 kg (BMI 29.2). She received timed sequential chemotherapy combining mitoxantrone 12 mg/m 2 /day for 3 days, etoposide 200 mg/m 2 /day for 3 days, and cytarabine 500 mg/m 2 /day for two sequences of 3 days. 12 After CR achievement, the patient who had a suitable donor received allogeneic bone marrow transplantation in September 1990. Conditioning regimen included cyclophosphamide 60 mg/kg/day for 2 days and busulfan 4 mg/kg/day for 4 days. Graft-versus-host disease (GVHD) prophylaxis was performed by a combination of cyclosporin A and methotrexate. Aplasia was only marked by cutaneous GVHD (grade I) and serological conversion for the cytomegalovirus (CMV). Overall, the patient had received 585 mg of daunorubicin during treatment. She also received 64 mg of mitoxantrone and 9000 mg of cyclophosphamide while she would have received, respectively, only 58 mg and 7200 mg if she had presented with 'ideal' weight as defined by standard height-weight tables. 10 The patient was rehospitalized by October 1990 because of cardiomyopathy referring to myocardial damage that occurs in association with chemical toxicity. The echocardiogram showed a cardiac left-sided dilatation with globally hypokinetic ventricle and mitral valve functional disease. Despite a symptomatic medical treatment, she was regularly hospitalized as congestive heart failure progressed. She finally died in January 1996 (5. years after achieving a second CR) awaiting cardiac transplantation.
We confirmed in European APL patients the results previously described in American patients. 6 The BMI tends to be higher in APL patients compared with that of patients with other leukemia subtypes. No etiology has been recognized until now. However, a relationship between ethnicity and increased BMI has been suggested, 6 APL cases being more frequent in patients from Latino origin. 13 Our two APL cases report the involvement of increased BMI in the administration of overdosed chemotherapy responsible for severe cardiac failure requiring consideration of cardiac transplantation.
First of all, these observations point to the need for reconsidering the calculation of antileukemic agent doses that are classically determined by reporting the therapeutic schedule to body-surface area. Our two patients were overdosed and developed congestive heart disease because of anthracycline and/or cyclophosphamide cumulative toxicity. Administered doses exceeded from 22, 10 and 25% respectively the doses of daunorubicin, mitoxantrone and cyclophosphamide that they might normally have received in the absence of obesity. In patients presenting with increased BMI, 'adapted' doses of chemotherapy based on 'ideal' weight or evaluated independently of the fat mass seem, then, more accurate than conventional doses determined on body-surface area. The rate of clearance of antileukemic agents differs from one patient to another 14 suggesting a possible determination of 'individualized' chemotherapy based on the clearance of drugs. In obese patients, it could be expected that adjusting the dose of antileukemic agents to account for the patient's ability to clear the drug can decrease treatment toxicity, while preserving a favorable outcome.
Secondly, these observations point to reconsidering some aspects of current treatment schedules in APL. The most striking improvement has come from the introduction of ATRA as differentiating therapy. Little resistance occurs and failure is only due to toxic death.
15 Achievement of better results seems then to depend on the improvement of treatment tolerability. Despite anthracyclines having been recognized as therapeutic agents of choice in APL, their wide use may be questionable since the introduction of ATRA. Patients treated with ATRA alone usually relapse and chemotherapy is still useful for CR continuation. Recent results have shown superiority of the combination of ATRA and anthracycline-cytarabine chemotherapy compared with ATRA followed by chemotherapy. 15 However, less toxic regimens could be evaluated in front-line therapy in order to prevent serious adverse events and cardiotoxic drug cumulative effects. Standard chemotherapy combined with ATRA can consistently yield long survival, but has never been compared to the same regimens including less anthracyclines. Another concern for preserving cardiac function is the long survival observed in this subtype of AML. 9 After relapse, patients re-treated with ATRA could still obtain a long second CR. 5 It then seems reasonable in front-line therapy to decrease drug toxicity in order to preserve the future, knowing that even in the case of relapse a long survival can still be expected.
The optimal choice of post-remission therapy in APL remains controversial. Recent results suggest a benefit to prolonged continuous maintenance therapy with 6-MP and methotrexate combined with ATRA. 15 Intensive therapy using transplantation allows a greater probability of long survival in AML, while increasing the risk of toxicity related to conditioning regimens. Its advantage in APL has not been demonstrated, although encouraging data with eradication of cells carrying the specific PML-RAR␣ transcript have been described after bone marrow transplantation. 16 Finally, we question the method of cardiotoxic drug administration and their combination with other drugs. For cardiotoxic compounds, rapid intravenous infusions may present unacceptable dangers, but intermediate-length infusions may reduce peak drug levels adequately while retaining some of the convenience of bolus dosing. This may provide a means of overcoming the acute toxicities that are produced by the delivery of high peak drug levels to target organs.
We conclude that determination of BMI is an important factor that must be systematically taken into account in the treatment of APL patients. Its increased value requires a prudent use of cardiotoxic agents and appropriate modifications in calculation of drug doses.
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